| Literature DB >> 30256515 |
Molly M Lamb1, Bo Cai2, Julie Royer3, Shree Pandya4, Aida Soim5, Rodolfo Valdez6, Carolyn DiGuiseppi1, Katherine James1, Nedra Whitehead7, Holly Peay7, Swamy Y Venkatesh8, Dennis Matthews9.
Abstract
To describe the long-term effect of steroid treatment on weight in nonambulatory males with Duchenne Muscular Dystrophy (DMD), we identified 392 males age 7-29 years with 4,512 weights collected after ambulation loss (176 steroid-naïve and 216 treated with steroids ≥6 months) from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Comparisons were made between the weight growth curves for steroid-naïve males with DMD, steroid-treated males with DMD, and the US pediatric male population. Using linear mixed-effects models adjusted for race/ethnicity and birth year, we evaluated the association between weight-for-age and steroid treatment characteristics (age at initiation, dosing interval, cumulative duration, cumulative dose, type). The weight growth curves for steroid-naïve and steroid-treated nonambulatory males with DMD were wider than the US pediatric male growth curves. Mean weight-for-age z scores were lower in both steroid-naïve (mean = -1.3) and steroid-treated (mean = -0.02) nonambulatory males with DMD, compared to the US pediatric male population. Longer treatment duration and greater cumulative dose were significantly associated with lower mean weight-for-age z scores. Providers should consider the effect of steroid treatment on weight when making postambulation treatment decisions for males with DMD.Entities:
Keywords: corticosteroids; muscular dystrophy; nonambulatory; weight
Mesh:
Substances:
Year: 2018 PMID: 30256515 PMCID: PMC7533648 DOI: 10.1002/ajmg.a.40517
Source DB: PubMed Journal: Am J Med Genet A ISSN: 1552-4825 Impact factor: 2.802